China's import and export of traditional Chinese medicine generally improved in the first three quarters

The import and export volume continued to grow steadily The traditional market still maintained its advantage In the first three quarters of this year, the import and export volume of traditional Chinese medicine products in China was US $2.43 billion, up 10.53% year on year Among them, the export volume was 1.8 billion US dollars, up 7.20% year on year; the import volume was 630 million US dollars, up 21.32% year on year Most of the exports of traditional Chinese medicine products in China have increased in varying degrees The export volume of the largest commodity is still plant extracts, with a year-on-year growth of 6.07% to 855 million US dollars; the export volume of traditional Chinese medicine and decoction pieces is 588 million US dollars, with a year-on-year growth of 6.55%, ranking the second; the export volume of proprietary Chinese medicine is 199 million US dollars, with a year-on-year growth of 17.84%; the export volume of health products is 159 million US dollars, with a year-on-year growth of 3.71% The traditional Chinese medicine market remains dominant Japan, Hong Kong, the European Union, the United States and South Korea are still the main export markets of traditional Chinese medicine The export volume of these five markets accounts for 71.45% of the total export volume of traditional Chinese medicine Among them, the growth of our exports to Hong Kong, China and the European Union slowed down, while the growth of our exports to Japan, South Korea and the United States was relatively obvious, reaching 25.76%, 32.42% and 21.81% respectively, which became an important driving force for the substantial increase of exports of traditional Chinese medicine Last year, China's exports of traditional Chinese medicine to Germany increased by 85% year-on-year due to the increased demand for ginseng and some extract products from Germany With the order volume from Germany stable this year, China's exports of traditional Chinese medicine to Germany fell by 6.6% in the first three quarters of this year As the global economic growth slows down and the growth is uncertain, the export growth of Chinese traditional medicine to various markets slows down as a whole In the first three quarters of this year, the traditional market of China's extract export still maintained a stable growth, and the demand of some new markets (such as Mexico and ASEAN markets in Latin America) declined year on year In the first three quarters of this year, China's exports of Chinese herbal medicines and pieces of decoction as a whole maintained a steady growth The demand of traditional markets such as Japan and South Korea increased by more than 20% year-on-year, but the demand of Latin America and Africa fell sharply year-on-year In addition, influenced by Taiwan's implementation of control measures on imported Chinese herbal medicines, the export volume of Chinese herbal medicines and pieces of decoction from mainland China to Taiwan in the first three quarters of this year was only US $1997 million, down 49% year on year In the first three quarters of this year, the export of Chinese patent medicine increased by 17.84% year on year Among them, the proportion of EU in the export of Chinese patent medicine decreased from 6.47% in 2010 to 2.59% The proportion of Chinese patent medicine exports from the mainland to Hong Kong is rising Private enterprises have become the main force to promote the import and export of traditional Chinese medicine In the first three quarters of this year, private enterprises were the main force of export, with 2022 exporters, with an export volume of 915 million US dollars, accounting for 50.81%; 334 enterprises with "three foreign capital", with an export volume of 524 million US dollars, accounting for 29.12%; and only 19.97% of state-owned enterprises In the first three quarters of this year, China's exports of Chinese patent medicines to EU countries were US $7.7 million, down 37.61% year on year The declining share of export of traditional Chinese medicine is in sharp contrast to the growing export of raw materials Various trade barriers such as overseas registration and certification are the main reasons that restrict the growth of export of traditional Chinese medicine, and the process of its going abroad is still slow In 2004, the directive on traditional herbal medicines (hereinafter referred to as the directive) issued by the European Union has had a direct impact on the export of Chinese patent medicines to the European Union The directive stipulates that all Chinese patent medicines sold in the European Union market must be registered in accordance with the new regulations before April 30, 2011, and get the listing license, otherwise they are not allowed to be sold In 2011, China exported US $13.32 million of Chinese patent medicines to Europe, with a year-on-year decrease of 13.5% But this year, China's export of Chinese patent medicine has been affected by the EU directive The Dutch and Romanian markets are basically stable, and Germany's demand is still growing Only Britain is becoming more and more strict in its management of the export of Chinese patent medicines In the first three quarters of this year, China's exports of Chinese patent medicines to the UK fell by 77% year on year Because the UK accounts for a large proportion of the export market of Chinese patent medicine to the EU, the sharp decline in the export to the country has also increased the decline rate of the overall data of Chinese patent medicine export to the EU.